Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

RAVEN: A phase I/II trial treating relapsed acute lymphoblastic leukemia with venetoclax and navitoclax

Acute Lymphoblastic Leukemia

Approximately a quarter of all childhood malignancies are acute lymphoblastic leukaemia (ALL). Front-line therapy will cure the majority of patients, however 10-20% of children will experience a relapse. The outcomes of children with relapsed or refractory (did not respond to treatment) ALL and lymphoma (rALL) are poor, with an early relapse (within 3 years from their diagnosis) indicative of a poorer prognosis.

RAVEN is a phase I/II clinical trial evaluating the activity of venetoclax and navitoclax in conjunction with combination chemotherapy in children with relapsed or refractory acute lymphoblastic leukaemia or lymphoma.

Venetoclax is a new anti-cancer drug, co-developed and trialled at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Victoria. It has already shown outstanding results in several clinical trials including triggering remission in patients with advanced forms of leukaemia for whom treatment options had been exhausted (including ALL). Both venetoclax and navitoclax were largely developed in Australia by researchers at the WEHI.

RAVEN will test the safety of these drugs in children and provide initial data regarding their effectiveness to treat children with relapsed and refractory ALL and lymphoma.

Disease stage: Relapsed or refractory

Patient age range: 4 to 21 years of age

Trial Sponsors:

  • National – ANZCHOG
  • International – St Jude Children’s Research Hospital, Memphis (U.S.)

RAVEN is proudly supported by the Leukaemia Foundation, Snowdome Foundation and Minderoo Foundation.